Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Wajeeh Khan

AMLX Stock Soars as Amylyx GLP-1 Drug Succeeds in Late-Stage Trial

Amylyx (AMLX) stock ripped higher on Tuesday after the pharmaceutical firm reported promising Phase 3 clinical trial data for its candidate drug, avexitide.

In its press release, AMLX said its avexitide, a first-in-class GLP-1 receptor antagonist for post-bariatric hypoglycemia, demonstrated a 55% reduction in hypoglycemic events in the Lucidity trial.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.